Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Inclusion Criteria

• •At least 18 years old at confirmed diagnosis with metastatic non-small cell lung cancer (NSCLC) (stage IV), squamous or non-squamous histology
• •Initiated first-line (1L) combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (NIC) regimen between 01 January 2018 and 2 years prior to study launch
• •Tumor programmed death-ligand 1 (PD-L1) negative expression (i.e., PD-L1 \<1%)
• •No EGFR, ALK, or ROS1 genetic mutation (i.e., wild type)
• •Minimum of 6 months of follow-up after initiation of 1L NIC\*